TP53 and cancer: We investigated p53-dependent (re-)sensitization of mutp53(E285K)-expressing M#31 cells to cisplatin-induced cell death using three compounds, COTI-2, PEITC, and PRIMA1-Met which have been included into multiple clinical trials (https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/mutant-p53-activator-coti-2; https://clinicaltrials.gov/ct2/show/NCT00691132; https://aacrjournals.org/mct/article/12/11/2331/91591/PRIMA-1Met-APR-246-Displays-High-Antitumor; [16]).